The first domestic patent nullity of Humira will stimulate biosimilar development
One of domestic patents of Humira(Abbvie), a TNF-Alpha inhibitor used mainly in rheumatoid arthritis treatment, has been ruled to be nullified.
Thus, biosimilar development of domestic pharmaceutical companies, such as Samsung Bioepis, LG Life Sciences and Celltrion, is expected to be triggered....
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
